Researchers search for a method before they search for a provider.
Omics service search runs on platform, technique and analyte queries typed by scientists mid-protocol — a vocabulary that marketing pages about insight and discovery never match.
A researcher looking for an omics provider searches by the technique they need: an instrument platform, a labelling approach, a quantification method, a specific analyte panel or a sample type they are struggling with. They almost never search for a services category. Pages built around service lines therefore match nothing, while a page for each method — with the instrumentation, the preparation, the quality control and the expected coverage — meets the query exactly and reaches the person who will specify the supplier, even though someone else signs the purchase order.
Scientists evaluating a provider have usually been disappointed before, and they read promotional phrasing as a warning sign. Pages promising to unlock insight or accelerate discovery are dismissed within seconds, and the bounce is not merely a lost visit — it is a signal that the page did not answer the query. Writing at the level of a methods section, with real figures and honest limitations, performs better on every measure that matters here. It is also considerably harder for a competitor to imitate than a page of adjectives.
Work run on your platform ends up in papers, and those papers cite the method and often the provider. Most omics companies never connect that to their website, so the citation accrues to nobody. Maintaining a publications section that lists studies using your services, with the method used and a link to the source, creates pages that researchers genuinely search for, attracts links from institutional and lab pages, and demonstrates capability far more convincingly than any claim. The material already exists; it is a question of collecting and presenting it.
Before a researcher decides to outsource, they usually try to solve the problem themselves and search accordingly: why a sample is degrading, how to normalise a dataset, which extraction suits a tissue type. Answering those questions properly puts you in front of the decision weeks before an enquiry, and it builds the topical depth that a small domain needs in order to rank for anything competitive. Much of this content already exists inside your technical support correspondence, which makes it the cheapest material available to you.
What arrives at the end of a project — file formats, raw and processed data, pipeline versions, retention, whether reanalysis is included, who owns the output — determines whether a service fits an existing workflow, and researchers search these questions explicitly. Almost no provider answers them publicly, so the results page is close to empty. Publishing them plainly shortens the sales conversation, ranks quickly because the competition is thin, and signals an operational maturity that abstract capability claims cannot convey.
The population of researchers who might commission an omics project is small, geographically dispersed and highly specific. Judging this work by traffic volume misreads it entirely: a month producing thirty visits from four institutions and two technically detailed enquiries is a strong month. The metrics worth tracking are which methods pages attract enquiries, which institutions appear, and whether the enquiries arrive already understanding your platform — which shortens the sales cycle far more visibly than it changes any traffic chart.
What comes up when planning search visibility for a metabolomics or multi-omics service.
Yes. Keyword tools are unreliable at low volumes and report zero for many legitimate scientific terms, which is a limitation of their data rather than evidence of no demand. Method names, analyte panels and instrument platforms are searched by exactly the people who commission this work. Search Console will show you the real queries once the pages exist, and in this sector that is usually the first accurate picture a provider has ever had.
For the scientist, with a clear summary for the approver. The scientist evaluates the method and decides whether to recommend you; the budget holder confirms cost, timeline and reliability. Writing to the middle loses the scientist without satisfying the approver, and the scientist is the one who determines whether the request is made at all. A methods-level page with a short, plain section on turnaround, deliverables and pricing structure serves both honestly.
By being more specific rather than broader. Large providers cover many methods shallowly because they have to; a specialist can publish genuine depth on a narrower set — real performance figures, honest limitations, worked examples with actual data. That depth ranks for the precise queries a researcher types when they already know what they need, which is the traffic worth having. Competing on breadth against a larger site is a contest you cannot win and do not need to enter.
Rarely, in practice. Your competitors already know the instruments and the standard approaches, and what they cannot copy is your validation data, your quality control and your track record. What withholding methods does cost is the researcher who needed to verify that your approach suited their sample and could not, so they went elsewhere. Protecting genuinely proprietary steps while publishing the rest is both safe and considerably more effective.
Method pages that researchers would find if they existed, and marketing language on the pages that do. Tell us which platforms and panels you run and we will tell you what a scientist searching for them finds today.